nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.01.2008 | Original article

⁶⁸Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors

verfasst von: C. Pettinato, A. Sarnelli, M. Di Donna, S. Civollani, C. Nanni, G. Montini, D. Di Pierro, M. Ferrari, M. Marengo, C. Bergamini

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The aim of this work was the evaluation of biodistribution and radiation dosimetry of ⁶⁸Ga-DOTANOC in patients affected by neuroendocrine tumors.

Materials and methods

We enrolled nine patients (six male and three female) affected by different types of neuroendocrine tumors (NETs). Each patient underwent four whole body positron emission tomography (PET) scans, respectively, at 5, 20, 60, and 120 min after the intravenous injection of about 185 MBq of ⁶⁸Ga-DOTANOC. Blood and urine samples were taken at different time points post injection: respectively, at about 5, 18, 40, 60, and 120 min for blood and every 40–50 min from injection time up to 4 h for urine. The organs involved in the dosimetric evaluations were liver, heart, spleen, kidneys, lungs, pituitary gland, and urinary bladder. Dosimetric evaluations were done using the OLINDA/EXM 1.0 software.

Results

A physiological uptake of ⁶⁸Ga-DOTANOC was seen in all patients in the pituitary gland, the spleen, the liver, and the urinary tract (kidneys and urinary bladder). Organs with the highest absorbed doses were kidneys \( \left( {{{9.0{\text{E}} - 02 \pm 3.2{\text{E}} - 02{\text{mSv}}} \mathord{\left/ {\vphantom {{9.0{\text{E}} - 02 \pm 3.2{\text{E}} - 02{\text{mSv}}} {{\text{MBq}}}}} \right. \kern-\nulldelimiterspace} {{\text{MBq}}}}} \right) \). The mean effective dose equivalent (EDE) was \( {{2.5{\text{E}} - 02 \pm 4.6{\text{E}} - 03{\text{mSv}}} \mathord{\left/ {\vphantom {{2.5{\text{E}} - 02 \pm 4.6{\text{E}} - 03{\text{mSv}}} {{\text{MBq}}}}} \right. \kern-\nulldelimiterspace} {{\text{MBq}}}} \).

Discussion and conclusions

The excretion of the compound was principally via urine, giving dose to the kidney and the urinary bladder wall. As SSTR2 is the most frequently expressed somatostatin receptor and ⁶⁸Ga-DOTANOC has high affinity to it, this compound might play an important role in PET oncology in the future. The dosimetric evaluation carried out by our team demonstrated that ⁶⁸Ga-DOTANOC delivers a dose to organs comparable to, and even lower than, analogous diagnostic compounds.

Maecke HR, Hofmann M, Haberkorn U. ⁶⁸Ga-labeled peptides in tumor imaging. J Nucl Med 2005;46 suppl.1:172S–8S.PubMed

Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228–47.PubMedCrossRef

Behr TM, Gotthardt M, Barth A, Behe M. Imaging tumors with peptide-based radioligands. Q J Nucl Med 2001;45:189–200.PubMed

Kwekkeboom DJ, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000;41:1704–13.PubMed

Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, et al. Somatostatin receptormediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001;28:1421–9.PubMedCrossRef

Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. ⁶⁸Ga-DOTA-Tyr³-Octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508–18.PubMedCrossRef

Forster GJ, Engelbach M, Brockmann JJ, Reber HJ, Buchholz HG, Macke HR, et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumors: comparison of ⁸⁶Y-DOTATOC and ¹¹¹In-DTPA-octreotide. Eur J Nucl Med 2001;28:1743–50.PubMedCrossRef

Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptors therapy: a review. J Nucl Med 2006;47:1467–75.PubMed

Cremonesi M, Ferrari M, Zoboli S, Chinol M, Stabin MG, Orsi F, et al. Biokinetics and dosimetry in patients administered with ¹¹¹In-DOTA-Tyr³-octreotide: implications for internal radiotherapy with ⁹⁰Y-DOTATOC. Eur J Nucl Med 1999;26:877–86.PubMedCrossRef

10.

Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [⁶⁸Ga]-DOTA-DPhe1-Tyr³-Octreotide in comparison to [¹¹¹In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5:42–8.PubMedCrossRef

11.

Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher, Strauss LG, Doll J, et al. Characterization of ⁶⁸Ga-DOTA-D-Phe1-Tyr³-Octreotide kinetics in patients with meningiomas. J Nucl Med 2005;46:763–9.PubMed

12.

Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand ⁶⁸Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751–7.PubMedCrossRef

13.

Henze M, Schumacher T, Hipp P, Kowalski J, Becker DW, Doll J, et al. PET imaging of somatostatin receptors using [⁶⁸Ga]DOTA-D-Phe1-Tyr³-octreotide: first results in patients with meningiomas. J Nucl Med 2001;42:1053–6.PubMed

14.

Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338–47.PubMedCrossRef

15.

Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H, et al. ⁶⁸Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 2005;724.

16.

Baum R, Niesen A, Leonhardi J, Wortmann R, Mueller D, Roesch F. Receptor PET/CT imaging of neuroendocrine tumors using the Ga-68 labelled, high affinity somatostatin analogue DOTA-1-Nal3 octreotide (DOTA-NOC): clinical results in 327 patients. Eur J Nucl Med Mol Imaging 2005;32 Suppl 1:S54–5.

17.

Roesch F, Zhernosekov K, Filosofov D, Jahn M, Jennewein M, Baum R, et al. Processing of Ge-68/Ga-68 generator eluates for labeling of biomolecules via bifunctional chelators. J Nucl Med 2006;47 Suppl 1:162P.

18.

Schuhmacher J, Maier-Borst W. A new ⁶⁸Ge/⁶⁸Ga radioisotope generator system for production of ⁶⁸Ga in dilute HCl. Int J Appl Radiat Isot 1981;32:31–6.CrossRef

19.

Breeman WA, de Jong M, de Blais E, Bernard BF, Konjinemberg M, Krenning EP. Radiolabelling DOTA-peptides with ⁶⁸Ga. Eur J Nucl Med Mol Imaging 2005;32:478–85.PubMedCrossRef

20.

Schmidtlein CR, Kirov AS, Nehmeh SA, Erdi YE, Humm JL, Amols HI, et al. Validation of GATE Monte Carlo simulations of the GE Advance/Discovery LS PET scanners. Med Phys 2006;33 (1):198–208, Jan.PubMedCrossRef

21.

Bettinardi V, Danna M, Savi A, Lecchi M, Castiglioni I, Gilardi MC, et al. Performance evaluation of the new whole-body PET/CT scanner: discovery ST. Eur J Nucl Med Mol Imaging 2004;31:867–81.PubMedCrossRef

22.

Beyer T, Antoch G, Muller S, Egelhof T, Freudenberg LS, Debatin J, et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med 2004;45:25S–35S.PubMed

23.

Townsend DW, Carney JPJ, Yap JT, Hall NC. PET/CT today and tomorrow. J Nucl Med 2004;45:4S–14S.PubMed

24.

Carney JP, Townsend DW, Rappoport V, Bendriem B. Method for transforming CT images for attenuation correction in PET/CT imaging. Med Phys 2006;33 4:976–83, Apr.PubMedCrossRef

25.

Stabin M, Siegel J, Hunt J, Sparks R, Lipsztein J, Eckerman K. RADAR: the radiation dose assessment resource—an online source of dose information for nuclear medicine and occupational radiation safety [abstract]. J Nucl Med 2002;42 suppl:243P.

26.

Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.PubMed

27.

Cristy M, Eckerman K. Specific absorbed fractions of energy at various ages from internal photons sources. Oak Ridge, TN: Oak Ridge National Laboratory; 1987:V1-V7. ORNL/TM-8381.

28.

Stabin M, Watson E, Cristy M, Ryman J, Eckerman K, Davis J, et al. Mathematical models and specific absorbed fractions of photon energy in the nonpregnant adult female and at the end of each trimester of pregnancy. Oak Ridge, TN: Oak Ridge National Laboratory; 1995. ORNL report ORNL/TM-12907.

29.

Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689–94.PubMed

30.

Stabin MG, Siegel JA, Sparks RB, Eckerman KF, Breitz HB. Contribution to red marrow absorbed dose from total body activity: a correction to the MIRD Method. J Nucl Med 2001;42:492–8.PubMed

31.

Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982–93.PubMedCrossRef

32.

Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumors: molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med Mol Imaging 2003;30:781–93.PubMedCrossRef

33.

Kwekkeboom DJ, Kooij PP, Bakker WH, Macke HR, Krenning EP. Comparison of ¹¹¹In-DOTA-Tyr³-octreotide and ¹¹¹In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 1999;40:762–7.PubMed

34.

Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, et al. Evaluation of the pharmacokinetics of ⁶⁸Ga-DOTATOC in patients with metastatic neuroendocrine tumors scheduled for ⁹⁰Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33 4:460–6, Apr.PubMedCrossRef

Titel: 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors
verfasst von: C. Pettinato
A. Sarnelli
M. Di Donna
S. Civollani
C. Nanni
G. Montini
D. Di Pierro
M. Ferrari
M. Marengo
C. Bergamini
Publikationsdatum: 01.01.2008
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2008
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0587-y

Springer Medizin

Abstract

Objectives

Materials and methods

Results

Discussion and conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas

Avid uptake of [18F]-FDG in fibrous dysplasia can mimic skeletal involvement in Hodgkin’s disease

Could choline PET play a role in malignancies other than prostate cancer?

Intestinal accumulation of 99mTc-MDP in a patient with protein-losing enteropathy

The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer

In vivo amyloid imaging with PET in frontotemporal dementia